

HOMCY CHARLES J  
Form 5  
February 14, 2018

# FORM 5

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0362  
Expires: January 31, 2005  
Estimated average burden hours per response... 1.0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).  
Form 3 Holdings Reported Form 4 Transactions Reported

**ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person \*  
HOMCY CHARLES J

2. Issuer Name and Ticker or Trading Symbol  
Global Blood Therapeutics, Inc. [GBT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)  
12/31/2017

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BLVD, SUITE 300

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Reporting

(check applicable line)

SOUTH SAN FRANCISCO, CA 94080

(City) (State) (Zip)

Form Filed by One Reporting Person  
 Form Filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/06/2017	^	J(1)	7,798 D \$ 0	34,877	D	^
Common Stock	04/13/2017	^	J(2)	7,798 A \$ 0	22,841	I	By Charles Homcy Revocable Trust

Edgar Filing: HOMCY CHARLES J - Form 5

Common Stock	05/17/2017	Â	J <sup>(3)</sup>	3,277	D	\$ 0	31,610	D	Â
Common Stock	05/25/2017	Â	J <sup>(4)</sup>	3,277	A	\$ 0	26,118	I	By Charles Homcy Revocable Trust
Common Stock	06/14/2017	Â	J <sup>(5)</sup>	1,504	D	\$ 0	30,106	D	Â
Common Stock	06/21/2017	Â	J <sup>(6)</sup>	1,504	A	\$ 0	27,622	I	By Charles Homcy Revocable Trust
Common Stock	07/28/2017	Â	J <sup>(7)</sup>	112,685	A	\$ 0	140,307	I	By Charles Homcy Revocable Trust
Common Stock	09/21/2017	Â	J <sup>(8)</sup>	2,563	D	\$ 0	27,543	D	Â
Common Stock	09/26/2017	Â	J <sup>(9)</sup>	2,563	A	\$ 0	142,870	I	By Charles Homcy Revocable Trust
Common Stock	10/26/2017	Â	J <sup>(10)</sup>	70,000	D	\$ 0	72,870	I	By Charles Homcy Revocable Trust
Common Stock	11/21/2017	Â	J <sup>(11)</sup>	6,359	D	\$ 0	21,184	D	Â
Common Stock	11/28/2017	Â	J <sup>(12)</sup>	6,359	A	\$ 0	79,229	I	By Charles Homcy Revocable Trust
Common Stock	Â	Â	Â	Â	Â	Â	1,600	I	By Charles Homcy Revocable Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 2270 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction	5. Number	6. Date Exercisable and Expiration Date	7. Title and Amount of	8. Price of Derivative	9. of
------------------------	---------------	--------------------------------------	-------------------------------	----------------	-----------	---	------------------------	------------------------	-------

Edgar Filing: HOMCY CHARLES J - Form 5

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Month/Day/Year)	Code (Instr. 8)	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)	Underlying Securities (Instr. 3 and 4)	Security (Instr. 5)	D
				(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HOMCY CHARLES J C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO, CA 94080	X	X	X	X

## Signatures

/s/ Lesley Calhoun as Attorney-in-Fact for the Reporting Person 02/14/2018

\*\*Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 7,798 shares received by the Reporting Person in a distribution-in-kind by Third Rock Ventures II, L.P. ("TRV II"), which distribution was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
  - (2) These shares were subsequently transferred to the Reporting Person's revocable trust on April 13, 2017. This report is being filed with respect to this transaction solely to correct the total number of shares directly and indirectly held by the Reporting Person immediately following the transaction.
- (3) Includes 3,277 shares received by the Reporting Person in a distribution-in-kind by TRV II, which distribution was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
  - (4) These shares were subsequently transferred to the Reporting Person's revocable trust on May 25, 2017. This report is being filed with respect to this transaction solely to correct the total number of shares directly and indirectly held by the Reporting Person immediately following the transaction.
- (5) Includes 1,504 shares received by the Reporting Person in a distribution-in-kind by TRV II, which distribution was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
  - (6) These shares were subsequently transferred to the Reporting Person's revocable trust on June 21, 2017. This report is being filed with respect to this transaction solely to correct the total number of shares directly and indirectly held by the Reporting Person immediately following the transaction.
    - (7) These shares were subsequently transferred to the Reporting Person's revocable trust on July 28, 2017. This report is being filed with respect to this transaction solely to correct the total number of shares directly and indirectly held by the Reporting Person immediately following the transaction.

## Edgar Filing: HOMCY CHARLES J - Form 5

- (8) Includes 2,563 shares received by the Reporting Person in a distribution-in-kind by TRV II, which distribution was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
- These shares were subsequently transferred to the Reporting Person's revocable trust on September 26, 2017. This report is being filed
- (9) with respect to this transaction solely to correct the total number of shares directly and indirectly held by the Reporting Person immediately following the transaction.
- (10) Represents trades for 70,000 shares previously reported on Form 4 filed by the Reporting Person on October 27, 2017. These trades are being included on this Form 5 solely to correct the form of ownership immediately following the transaction.
- (11) Includes 6,359 shares received by the Reporting Person in a distribution-in-kind by TRV II, which distribution was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
- These shares were subsequently transferred to the Reporting Person's revocable trust on November 28, 2017. This report is being filed
- (12) with respect to this transaction solely to correct the total number of shares directly and indirectly held by the Reporting Person immediately following the transaction.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.